Jes Pa Screening Positive Treatment

---
name: jes-pa-screening-positive-treatment
description: Recommends antihypertensive therapy including mineralocorticoid receptor antagonists (MRAs) for patients with a positive primary aldosteronism (PA) screening test who decline confirmatory testing. Triggers include when a patient has positive screening but refuses additional tests and asks "What should I treat with?" or initiates empiric therapy, with preference for MRAs in typical PA presentations (e.g., spontaneous hypokalemia, resistant hypertension, adrenal tumor on CT).
---

# Select antihypertensive treatment for PA-screen-positive patients avoiding further testing

## STEP 1 — Gather Information
Confirm PA screening positivity: ARR ≥200 (PAC/PRA) or PAC/ARC ≥40 with PAC ≥60 pg/mL by CLEIA. Document patient refusal of confirmatory testing (e.g., adrenal venous sampling, saline infusion test). Assess for typical PA features: spontaneous hypokalemia (<3.5 mEq/L), resistant hypertension, hypertension onset <40 years, adrenal tumor on CT, young-onset stroke, or sleep apnea syndrome.

## STEP 2 — Rule In / Rule Out
Is the patient refusing confirmatory testing?  
- Yes → Proceed to step 3 (empiric treatment pathway).  
- No → Recommend confirmatory testing per guideline (outside scope of this skill).

## STEP 3 — Classify or Stratify
Do typical PA clinical features are present?  
- Yes → Classify as typical PA (strong indication for MRA).  
- No → Classify as atypical PA (weaker indication; MRAs still an option).

## STEP 4 — Decide
If typical PA: Initiate MRA therapy (e.g., spironolactone 25–50 mg daily), monitor serum potassium and creatinine, titrate to blood pressure and potassium targets.  
If atypical PA: Initiate antihypertensive therapy including an MRA as a first-line option (e.g., spironolactone 25 mg daily) or alternative agents based on comorbidities; monitor for efficacy and adverse effects.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on screening in atypical cases without considering confirmatory testing if feasible. Avoid MRAs in hyperkalemia (K+ >5.0 mmol/L) or severe renal impairment (eGFR <30 mL/min/1.73 m²). Do not combine eplerenone or esaxerenone with potassium supplements. Monitor for gynecomastia with spironolactone, especially in men. Do not delay definitive diagnosis if symptoms worsen or hypokalemia persists. MRAs may mask biochemical cure; consider surgical evaluation if patient reconsiders testing.

## Concrete Clinical Example
A 58‑year‑old hypertensive patient with spontaneous hypokalemia (K+ 3.0 mEq/L) and a 1.2 cm adrenal nodule on CT has ARR 250 and PAC 80 pg/mL but refuses adrenal venous sampling. Typical PA features present → start spironolactone 25 mg daily, check K+ and creatinine in 1 week, up‑titrate to 50 mg daily if needed.

**Source:** Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2022, DOI: 10.1007/s00223-022-00903-0